CNS Penetration of Novel Targeted Agents and Immunotherapies in Hematologic Malignancies
This topic covers pharmacokinetic and pharmacodynamic data on BBB penetration by BTK inhibitors, BCL-2 inhibitors, bispecific antibodies, and XPO1 inhibitors — with a focus on CNS lymphoma and leptomeningeal disease.
Bispecific T-Cell Engagers in B-Cell Lymphoma: From Bench to Bedside
Comprehensive research on glofitamab, mosunetuzumab, epcoritamab, and other CD20×CD3 bispecific antibodies. Topics include mechanism of action, clinical trial data, CRS management, and intrathecal delivery strategies.
CAR-T Cell Therapy in CNS and High-Risk Hematologic Malignancies
CAR-T efficacy, toxicity (ICANS, CRS), CNS disease outcomes, manufacturing innovations, and next-generation CAR designs in DLBCL, ALL, and other B-cell malignancies.
TP53 Mutation as a Biomarker of Treatment Resistance in Aggressive B-Cell Lymphomas
Molecular and clinical data on TP53 mutation frequency, prognostic impact, and resistance to BCL-2 inhibition, XPO1 inhibition, and immunotherapy in DLBCL and related disorders.
Selinexor and XPO1 Inhibition in Relapsed/Refractory Lymphomas
Mechanism of XPO1 inhibition, clinical evidence in DLBCL and CNS lymphoma, dose optimization, and combination strategies with venetoclax, BTK inhibitors, and immunotherapies.
Intrathecal and Intraventricular Drug Delivery in CNS Lymphoma
Novel approaches to direct CNS drug delivery including intrathecal cytarabine, methotrexate, rituximab, and bispecific antibodies. Safety, efficacy, and pharmacokinetic data.
Minimal Residual Disease Monitoring and ctDNA in Aggressive Lymphomas
Liquid biopsy, circulating tumor DNA, and PET-CT approaches to MRD detection, treatment response monitoring, and early relapse prediction in DLBCL and related malignancies.
BCL-2 Family Proteins and Venetoclax Sensitivity: Predictive Biomarkers and Resistance Mechanisms
BCL-2 overexpression, apoptotic priming, venetoclax pharmacology, and mechanisms of de novo and acquired resistance in B-cell lymphomas and other hematologic malignancies.